- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07724795
IOL Power Formula Prediction Accuracy at the Extremes of Axial Length: A Prospective Outcome Verification Study (FORMULEX-OV)
Clinical Outcomes of Formula-dependent IOL Power Selection at the Extremes of Axial Length: a Cross-sectional Outcome Verification of Seven ESCRS-hosted Formulas and the Ladas Super Formula 2.0 in Short (<22.0 mm) and Long (>26.0 mm) Eyes Using Refractive, Biometric, and Tomographic Assessment
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Modern IOL power formulas achieve high refractive predictability in average-length eyes but deteriorate at the extremes of axial length, where effective lens position modelling diverges most between formulas. A preceding retrospective study at this center quantified the formula-dependent variability of IOL power recommendations at the axial length extremes using fully standardized biometric inputs; however, planning discrepancy alone does not indicate which formula's recommendation yields the better clinical outcome. This prospective outcome verification study closes that gap by linking a standardized postoperative assessment to the pre-existing, pseudonymized preoperative planning dataset.
Design: single-center, prospective, cross-sectional, observational (paired within-eye) study. From the retrospective source cohort (approximately 927 short and 769 long eyes; approximately 1,000-1,200 patients; index surgeries January 2022-December 2025), a stratified random sample of 200 patients is drawn (110 short stratum, 90 long stratum; 55:45 ratio) and invited to a single outcome visit. Each eligible eye contributes up to eight paired, formula-specific prediction errors that differ only by the calculation formula, while the postoperative reference (manifest refraction) and all preoperative inputs are held constant. Eyes are stratified a priori into a short (AL < 22.0 mm) and a long (AL > 26.0 mm) stratum and analyzed separately.
Formulas evaluated: Barrett Universal II, Cooke K6, EVO 2.0, Hill-RBF 3.0, Hoffer QST, Kane and PEARL-DGS (via the ESCRS IOL calculator), and the stand-alone Ladas Super Formula 2.0.
Outcome visit (single visit, all non-invasive standard ophthalmic techniques, no study-mandated therapy, medication or surgery): uncorrected and best-corrected distance visual acuity, IOLMaster 700 optical biometry, CASIA2 and Pentacam AXL corneal tomography, autorefraction and standardized subjective manifest refraction (primary outcome measure), slit-lamp examination with posterior capsule opacification grading, and macular OCT (obligatory in the long stratum, recommended in the short stratum).
Primary analysis: for each formula, the spherical equivalent prediction error (SE-PE = measured postoperative spherical equivalent minus the residual spherical equivalent predicted for the actually implanted IOL power step) is computed and the absolute error (|SE-PE|) compared globally across the eight formulas using the Friedman test, with post-hoc pairwise Wilcoxon signed-rank tests (Holm-corrected, 28 formula pairs), separately in each axial length stratum. The primary accuracy metric per formula is the median absolute prediction error.
All data are processed in pseudonymized form and linked via a study ID and laterality, in accordance with the Declaration of Helsinki (2024), ICH-GCP, and the GDPR. The study is reported per STROBE and is registered on ClinicalTrials.gov prior to the start of recruitment.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Michal Klimek, MD
- Número de teléfono: +436504607496
- Correo electrónico: klimek.michael@gmx.at
Ubicaciones de estudio
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, 1130
- Klinik Hietzing, Augenabteilung
-
Contacto:
- Michal Klimek, MD
- Número de teléfono: 06504607496
- Correo electrónico: michak485@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- - Participation in the retrospective IOL power formula comparison study at the extremes of axial length (pseudonymized study ID assigned; complete preoperative biometry and archived formula outputs for all eight formula pathways)
- Cataract surgery with a spherical (non-toric) IOL of one of the three reference models (HOYA Vivinex XY1, HOYA Vivinex Impress XY1-EM, or Johnson & Johnson Tecnis 1-Piece DIB00) at the study center between January 2022 and December 2025
- Preoperative axial length below 22.0 mm (short stratum) or above 26.0 mm (long stratum), measured on IOLMaster 700
- Documented implanted IOL model and power available from the operative record
- At least 3 months since cataract surgery at the time of the outcome visit
- Written informed consent for the outcome visit, including linkage of newly acquired postoperative data with the previously collected, pseudonymized preoperative planning data
Exclusion Criteria:
- - Interval ocular surgery on the study eye since the original cataract surgery that may affect refraction or IOL position (e.g., corneal refractive surgery, IOL exchange or repositioning, secondary IOL implantation, or any intraocular surgery). Uncomplicated YAG laser capsulotomy without IOL repositioning is not an exclusion criterion
- Implanted IOL not matching one of the three reference platforms (e.g., toric, multifocal or EDOF IOL, a different monofocal platform, or a sulcus-fixated IOL)
- Toric IOL implantation
- Acute ocular pathology preventing reliable refraction or biometric measurement
- Cognitive or physical limitations precluding standardized subjective manifest refraction
- Documented intraoperative complication with confirmed or suspected IOL malpositioning (e.g., posterior capsule rupture with vitreous loss, zonular dialysis requiring a capsular tension ring, sulcus placement)
- Withdrawal of informed consent
Note: macular pathology is not an exclusion criterion; macular status is documented on OCT and analyzed as a covariate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Short axial length stratum (AL < 22.0 mm)
Pseudophakic eyes with a preoperative axial length below 22.0 mm that received a spherical monofocal IOL.
These eyes undergo the standardized postoperative outcome visit; the measured spherical equivalent is compared with each formula's prediction for the implanted IOL power.
|
A single, non-invasive multimodal assessment: uncorrected and best-corrected distance visual acuity, IOLMaster 700 optical biometry, CASIA2 and Pentacam AXL corneal tomography, autorefraction and subjective manifest refraction, slit-lamp examination with posterior capsule opacification grading, and macular OCT.
No therapeutic intervention, medication or surgery is performed.
|
|
Long axial length stratum (AL > 26.0 mm)
Pseudophakic eyes with a preoperative axial length above 26.0
mm that received a spherical monofocal IOL.
These eyes undergo the standardized postoperative outcome visit (including obligatory macular OCT); the measured spherical equivalent is compared with each formula's prediction for the implanted IOL power.
|
A single, non-invasive multimodal assessment: uncorrected and best-corrected distance visual acuity, IOLMaster 700 optical biometry, CASIA2 and Pentacam AXL corneal tomography, autorefraction and subjective manifest refraction, slit-lamp examination with posterior capsule opacification grading, and macular OCT.
No therapeutic intervention, medication or surgery is performed.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Spherical equivalent prediction error (SE-PE) across eight IOL power formulas, compared within each axial length stratum
Periodo de tiempo: Single study visit, at least 3 months after cataract surgery
|
For each eye, SE-PE is calculated as the measured postoperative spherical equivalent (standardized manifest refraction) minus the residual spherical equivalent predicted by each formula for the actually implanted IOL power step.
The absolute prediction error (|SE-PE|) is compared globally across the eight formulas (Barrett Universal II, Cooke K6, EVO 2.0, Hill-RBF 3.0, Hoffer QST, Kane, PEARL-DGS, Ladas Super Formula 2.0) using the Friedman test, with post-hoc pairwise Wilcoxon signed-rank tests (Holm-corrected, 28 formula pairs), performed separately in the short (AL < 22.0 mm) and long (AL > 26.0 mm) strata.
The primary accuracy metric per formula is the median absolute prediction error (MedAE).
|
Single study visit, at least 3 months after cataract surgery
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- MA_15_EK_26_128_VK
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .